Zhongguancun announced that Beijing Huasu Pharmaceutical Co., Ltd., a subsidiary of the company, recently received the “Drug Registration Certificate” approved and issued by the State Drug Administration. Oxycodone hydrochloride sustained-release tablets passed the drug registration review and approval, and registration was approved. The drug is used to treat severe pain. Beijing Huasu is the fourth domestic company to be approved to apply for a marketing license for generic drugs of this specification. In 2025, domestic sample hospital terminal sales of the drug were 794 million yuan, and the total R&D cost of the project was about 17.5924 million yuan.

Zhongguancun announced that Beijing Huasu Pharmaceutical Co., Ltd., a subsidiary of the company, recently received the “Drug Registration Certificate” approved and issued by the State Drug Administration. Oxycodone hydrochloride sustained-release tablets passed the drug registration review and approval, and registration was approved. The drug is used to treat severe pain. Beijing Huasu is the fourth domestic company to be approved to apply for a marketing license for generic drugs of this specification. In 2025, domestic sample hospital terminal sales of the drug were 794 million yuan, and the total R&D cost of the project was about 17.5924 million yuan.